Newron Pharmaceuticals

Newron Pharmaceuticals (SIX: NWRN)

Currency in CHF

Last close As at 05/12/2023

CHF4.56

▲ −0.13 (−2.77%)

Market capitalisation

CHF81m

Overview
Price performance
Financials
Research
Sector insights
Thematics

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

Healthcare |
Update

11.10.23

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Healthcare |
Update

07.08.23

Newron Pharmaceuticals — Crucial upcoming datasets for evenamide

Healthcare |
Flash note

16.05.23

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Healthcare |
Flash note

20.03.23

Newron Pharmaceuticals — Positive top-line data to support clinical progress

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

Marco Caremi

Executive VP of Business Development
Stefan Weber

CEO

Balance Sheet

Forecast net cash (€m)

21.8

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(13.6)	(18.0)	237.8
Relative	(16.7)	(18.0)	244.9
52 week high/low	CHF8.0/CHF1.3

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). A potentially pivotal Phase III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS is underway; readouts are expected in Q423 or Q124. In the Phase II trial (study 014/015) for patients with TRS, evenamide has demonstrated both safety and efficacy in readouts to date. In October 2023, encouraging interim readouts were reported corresponding to the six-month timepoint for the full 161-patient cohort in extension study 015; full one-year data are expected in Q124. Newron intends to begin an additional, potentially pivotal, multinational Phase III study (study 003) in TRS patients (expected to start in Q124). In its H123 results, Newron recorded total revenue of €5.5m for the period, nearly double H122’s revenue of €2.8m, primarily driven by higher royalty income for Xadago.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2021A	5.8	(11.4)	(14.1)	(79.23)	N/A	N/A
2022A	6.1	(12.6)	(17.0)	(95.34)	N/A	N/A
2023E	8.9	(11.7)	(14.6)	(81.90)	N/A	N/A
2024E	6.8	(19.1)	(22.3)	(124.77)	N/A	N/A

Update

Healthcare

08.09.21

Newron Pharmaceuticals — Evenamide Phase III at 30mg twice daily dose

Update

Healthcare

18.05.21

Newron Pharmaceuticals — Long-term generic challenge to Xadago

Update

Healthcare

07.04.21

Newron Pharmaceuticals — Gate not yet open to Phase III

Update

Healthcare

29.03.21

Newron Pharmaceuticals — Dyskinesia deal delivered

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity Strategy and Market outlook – October 2023

Equity strategy and market outlook – September 2023

Equity strategy and market outlook – August 2023

Thematics

Latest

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

Deutsches Eigenkapitalforum (EKF) 2023 technology

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

About Edison

About Edison

Careers

Newron Pharmaceuticals (SIX: NWRN)

Latest Insights

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Newron Pharmaceuticals — Crucial upcoming datasets for evenamide

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Newron Pharmaceuticals — Positive top-line data to support clinical progress

Sector

Equity Analyst

Key Management

Balance Sheet

Share Price Performance

Financials

Newron Pharmaceuticals — Evenamide Phase III at 30mg twice daily dose

Newron Pharmaceuticals — Long-term generic challenge to Xadago

Newron Pharmaceuticals — Gate not yet open to Phase III

Newron Pharmaceuticals — Dyskinesia deal delivered

Newron Pharmaceuticals — Evenamide Phase II completes recruitment

Newron Pharmaceuticals — Schizophrenia development adds value

Newron Pharmaceuticals – EKF interview

Newron Pharmaceuticals — Evenamide trial progressing well

Newron Pharmaceuticals — Evenamide safety trial underway

Newron Pharmaceuticals — Evenamide focus, Supernus to sell Xadago in US

Newron Pharmaceuticals — Sarizotan fails to shine

Newron Pharmaceuticals — Seeing STARS

Newron Pharmaceuticals — Xadago slows, Evenamide lags but STARS ahead

Newron Pharmaceuticals — Evenamide down but not out

Newron Pharmaceuticals — Moving towards R&D inflection points

Newron Pharmaceuticals — Next up – R&D day

Newron Pharmaceuticals — 2018 focus on the CNS pipeline

Newron Pharmaceuticals — Xadago receives FDA approval in PD

Newron Pharmaceuticals — Marching into 2017

Newron Pharmaceuticals — Update 2 September 2016

Newron Pharmaceuticals — Update 31 March 2016

Newron Pharmaceuticals — Update 17 March 2016

Newron Pharmaceuticals — Update 14 March 2016

Newron Pharmaceuticals — Update 20 December 2015